Small Molecules

15 Feb 2022 First patient randomized in pivotal TRANSFORM study with setanaxib
15 Feb 2022 Primmune Therapeutics Presents Interim Analysis of Clinical Data from Phase 1 Study Evaluating PRTX007 at the Conference on Retroviruses and Opportunistic Infections (CROI 2022)
15 Feb 2022 Lynparza plus abiraterone reduced risk of disease progression by 34% vs. standard-of-care in 1st-line metastatic castration-resistant prostate cancer
15 Feb 2022 Lumakras® (sotorasib) shows encouraging and clinically meaningful anticancer activity in patients with KRAS G12C-mutated advanced pancreatic cancer in CODEBREAK 100 trial
13 Feb 2022 EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD
11 Feb 2022 AN2 Therapeutics Reports Phase 1b Data for Oral Epetraborole
11 Feb 2022 Maze Therapeutics Presents New Preclinical Data Supporting Advancement of MZE001 as a Potential Treatment for Pompe Disease
10 Feb 2022 Sumitomo Dainippon Pharma and Sumitovant Biopharma Initiate Phase 1 Study on New Drug Candidate for Carbapenem-Resistant Bacterial Infections
09 Feb 2022 CelerisTx in research collaboration with Merck KGaA, Darmstadt, Germany on AI-enabled degrader discovery
08 Feb 2022 Qurient Announces U.S. FDA Clearance of IND Application for Q901, a Novel Cancer Therapy
08 Feb 2022 Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer
08 Feb 2022 Shionogi Presents Phase 2/3 Clinical Trial Results (Phase 2a Part) for the COVID-19 Therapeutic Drug S-217622
07 Feb 2022 Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037
07 Feb 2022 Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors
04 Feb 2022 Cytokinetics Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure With Reduced Ejection Fraction
04 Feb 2022 Bayer will discontinue phase II development candidate eliapixant
04 Feb 2022 Pardes Biosciences Announces FDA Clearance of IND Application for PBI-0451, an Oral Antiviral Drug Candidate for the Treatment and Prevention of SARS-CoV-2 Infections
04 Feb 2022 UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results
03 Feb 2022 Kintor Pharma Announces Dosing of First Subject in US Phase I Clinical Trial of GT20029 for Androgenic Alopecia and Acne
02 Feb 2022 NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease
01 Feb 2022 ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV Treatment
01 Feb 2022 ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome
01 Feb 2022 Shionogi Presents Clinical Trial Results of the COVID-19 Therapeutic Drug S-217622
01 Feb 2022 Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health
01 Feb 2022 IDEAYA Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top